Dogwood Therapeutics, Inc. (DWTX)
Automate Your Wheel Strategy on DWTX
With Tiblio's Option Bot, you can configure your own wheel strategy including DWTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DWTX
- Rev/Share 0.0
- Book/Share 4.9162
- PB 0.9865
- Debt/Equity 10.7033
- CurrentRatio 7.4283
- ROIC -0.1639
- MktCap 9268981.0
- FreeCF/Share -8.6962
- PFCF -0.7394
- PE -0.318
- Debt/Assets 0.7821
- DivYield 0
- ROE -1.1654
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Published: August 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 -
Read More
Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Published: August 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, announced today that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 before the open of the financial markets.
Read More
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a corporate overview at the Sidoti Small-Cap Virtual Conference being held on Wednesday, June 11, 2025 – Thursday, June 12, 2025.
Read More
Dogwood Therapeutics Announces First Quarter 2025 Financial Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 - - Cash on hand of $17.5M provides operational runway through Q1 2026 - ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the first quarter ended March 31, 2025. “There are no FDA approved treatments to manage the neuropathic pain …
Read More
Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Published: May 01, 2025 by: Newsfile Corp
Sentiment: Neutral
Alpharetta, Georgia--(Newsfile Corp. - May 1, 2025) - Dogwood Therapeutics, Inc. (NASDAQ: DWTX), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Read More
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
Published: April 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million.
Read More
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders today announced it believes it has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). DWTX Chairman and CEO Greg Duncan stated, “We appreciate the consideration Nasdaq has shown Dogwood Therapeutics, Inc.” He continued, “The Company has a strong cash position of $17.5 million as of the end of Q1, with no debt, better positioning the Company to advance its continued mission to build …
Read More
About Dogwood Therapeutics, Inc. (DWTX)
- IPO Date
- Website https://www.dwtx.com
- Industry Biotechnology
- CEO Gregory Duncan
- Employees 12